ProMIS Neurosciences Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(expressed in US dollars)


· · Six Months Ended ·
· · June 30, ·
· 2025 · 2024 ·
Cash flows from operating activities
Net Loss	$(17,464,932)	$(6,258,745)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	457,310	81,583
Change in fair value of warrant liability	—	(44,954)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	620,912	603,865
Accounts payable	1,042,716	(5,827,969)
Accrued liabilities	6,562,946	(349,737)
Net cash used in operating activities	(8,781,048)	(11,795,957)

Cash flows from financing activities
Proceeds from issuance of Common Shares from ATM Offering, net of issuance costs	—	190,274
Net cash provided by financing activities	—	190,274

Net decrease in cash	(8,781,048)	(11,605,683)

Cash at beginning of period	13,291,167	12,598,146
Cash at end of period	$4,510,119	$992,463

Noncash financing activities
(Decrease) increase in share-based compensation liability on CAD denominated share options (increasing) decreasing additional paid-in-capital	$(136,868)	$43,486
Deferred financing costs included in accounts payable and accrued liabilities	$—	$99,555

Supplemental disclosure of cash flow information
Cash paid for interest	$—	$76,744

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.